Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.

Oakes TMM, Skljarevski V, Zhang Q, Kielbasa W, Hodsdon ME, Detke HC, Camporeale A, Saper JR.

Cephalalgia. 2018 May;38(6):1015-1025. doi: 10.1177/0333102417747230. Epub 2018 Jan 8.

PMID:
29310444
3.

A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition.

Kielbasa W, Pan A, Pereira A.

Eur Neuropsychopharmacol. 2015 Mar;25(3):377-85. doi: 10.1016/j.euroneuro.2014.12.009. Epub 2015 Jan 5.

PMID:
25637266
4.

A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.

Lin DY, Kratochvil CJ, Xu W, Jin L, D'Souza DN, Kielbasa W, Allen AJ.

J Child Adolesc Psychopharmacol. 2014 May;24(4):190-200. doi: 10.1089/cap.2013.0043.

5.

The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.

Kielbasa W, Tesfaye E, Luffer-Atlas D, Mitchell MI, Turik MA.

Eur J Clin Pharmacol. 2013 Dec;69(12):2011-9. doi: 10.1007/s00228-013-1572-y. Epub 2013 Aug 17.

6.

Clinical outcomes from an open-label study of edivoxetine use in pediatric patients with attention-deficit/hyperactivity disorder.

Jin L, Xu W, Krefetz D, Gruener D, Kielbasa W, Tauscher-Wisniewski S, Allen AJ.

J Child Adolesc Psychopharmacol. 2013 Apr;23(3):200-7. doi: 10.1089/cap.2012.0016.

PMID:
23607409
7.

Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder.

Kielbasa W, Quinlan T, Jin L, Xu W, Lachno DR, Dean RA, Allen AJ.

J Child Adolesc Psychopharmacol. 2012 Aug;22(4):269-76. doi: 10.1089/cap.2011.0151. Epub 2012 Jul 31.

PMID:
22849510
8.

Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses.

Kielbasa W, Stratford RE Jr.

Drug Metab Dispos. 2012 May;40(5):877-83. doi: 10.1124/dmd.111.043554. Epub 2012 Jan 27.

9.

Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder.

Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D, Gehlert DR, Marek G.

Eur Neuropsychopharmacol. 2010 Feb;20(2):80-7. doi: 10.1016/j.euroneuro.2009.10.005. Epub 2009 Dec 16.

PMID:
20018493
10.

A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.

Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P.

J Psychiatr Res. 2010 Apr;44(6):356-63. doi: 10.1016/j.jpsychires.2009.09.013. Epub 2009 Nov 11.

PMID:
19909980
11.

Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats.

Kielbasa W, Kalvass JC, Stratford R.

Drug Metab Dispos. 2009 Jan;37(1):137-42. doi: 10.1124/dmd.108.023119. Epub 2008 Oct 20.

12.

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism.

George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M.

Science. 2008 Mar 14;319(5869):1536-9. doi: 10.1126/science.1153813. Epub 2008 Feb 14.

13.

Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.

Seneca N, Gulyás B, Varrone A, Schou M, Airaksinen A, Tauscher J, Vandenhende F, Kielbasa W, Farde L, Innis RB, Halldin C.

Psychopharmacology (Berl). 2006 Sep;188(1):119-27. Epub 2006 Aug 4.

PMID:
16896954
16.

Nitrite inhalation in rats elevates tissue NOS III expression and alters tyrosine nitration and phosphorylation.

Kielbasa W, Fung HL.

Biochem Biophys Res Commun. 2000 Aug 28;275(2):335-42.

PMID:
10964667
17.
18.

Analysis of isobutyl nitrite inhalant in rat and human blood: application for pharmacokinetic investigations.

Kielbasa WB, Bauer JA, Fung HL.

J Chromatogr B Biomed Sci Appl. 1999 Oct 29;734(1):83-9.

PMID:
10574193

Supplemental Content

Loading ...
Support Center